# CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)

> **NCT04226248** · PHASE3 · COMPLETED · sponsor: **University of Bristol** · enrollment: 600 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Rivastigmine Transdermal System
- **OTHER:** Placebo Transdermal System

## Key facts

- **NCT ID:** NCT04226248
- **Lead sponsor:** University of Bristol
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-02
- **Primary completion:** 2024-05-02
- **Final completion:** 2025-07-24
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2025-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04226248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04226248, "CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04226248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*